Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: <scp>IKEMA</scp> subgroup analysis-Reference-Cited by-同舟云学术

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

Published:2022-06-04 Issue:1 Volume:98 Page:
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Dimopoulos Meletios A.¹^ORCID,Moreau Philippe²^ORCID,Augustson Bradley³,Castro Nelson⁴,Pika Tomas⁵,Delimpasi Sosana⁶^ORCID,De la Rubia Javier⁷,Maiolino Angelo⁸,Reiman Tony⁹,Martinez‐Lopez Joaquin¹⁰,Martin Thomas¹¹,Mikhael Joseph¹²^ORCID,Yong Kwee¹³,Risse Marie‐Laure¹⁴,Asset Gaelle¹⁵,Marion Sylvia¹⁶,Hajek Roman¹⁷¹⁸

Affiliation:

1. The National and Kapodistrian University of Athens Athens Greece

2. Department of Hematology University Hospital Hôtel‐Dieu Nantes France

3. Sir Charles Gairdner Hospital Perth Western Australia Australia

4. Hospital de Cancer de Barretos São Paulo Brazil

5. Department of Hemato‐Oncology University Hospital Olomouc Olomouc Czech Republic

6. Department of Haematology General Hospital of Athens Athens Greece

7. Hematology Department University Hospital La Fe Valencia Spain

8. Instituto COI de Ensino e Pesquisa and Faculdade de Medicina Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil

9. Department of Oncology, Saint John Regional Hospital Dalhousie University and University of New Brunswick Saint John New Brunswick Canada

10. Departamento de Hematología Hospital 12 de Octubre, Complutense University Madrid Spain

11. UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California USA

12. Translational Genomics Research Institute, City of Hope Cancer Center Phoenix Arizona USA

13. Department of Haematology University College Hospital London UK

14. Sanofi Vitry‐sur‐Seine France

15. Sanofi Chilly‐Mazarin France

16. Sanofi Cambridge Massachusetts USA

17. Department of Hemato‐Oncology University Hospital Ostrava Ostrava Czech Republic

18. Department of Hemato‐Oncology, Faculty of Medicine University of Ostrava Ostrava Czech Republic

Funder

Sanofi

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26602

Reference6 articles.

1. Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016

2. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

3. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

4. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

5. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of telemonitoring on correct drug use, complications and quality of life among patients with multiple myeloma (ITUMM): A study protocol for an open-label, parallel-group, randomized controlled trial;PLOS ONE;2024-08-26

2. Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma;Expert Opinion on Biological Therapy;2024-05-03

3. IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?;Life;2023-11-20

4. Multiple Myeloma in 2023 Ways: From Trials to Real Life;Current Oncology;2023-11-03

5. A safety review of recently approved and emerging drugs for patients with relapsed or refractory multiple myeloma;Expert Opinion on Drug Safety;2023-11-02